Table 3.
Survival data of the patient cohorts and subgroups in association with EBV and MSI status
| EBV and MSI status | No. | Events | Survival probability (%) | Median survival (month) | HR | P value* | |||
|---|---|---|---|---|---|---|---|---|---|
| 1 year | 3 years | 5 years | (95% CI) | (95% CI) | |||||
| Tumour biopsies before neoadjuvant CTx | MSS/EBV(−) | 116 | 66 | 74.6 | 52.0 | 44.6 | 37.9 (17.4–58.4) | 1 ref. | |
| EBV(+) | 5 | 3 | 100 | 60.0 | 40 | 56.5 (0.0–123.7) | 0.83 (0.26–2.64) | 0.754 | |
| MSI‐L | 6 | 2 | 100 | 100 | 100 | 62.2 (60.6–63.9) | 0.47 (0.12–1.93) | 0.297 | |
| MSI‐H | 15 | 6 | 92.2 | 61.9 | 54.2 | nr | 0.66 (0.29–1.53) | 0.333 | |
| Total | 142 | 77 | 78.3 | 55.1 | 47.3 | 48.1 (26.2–70.0) | |||
| Resected tumours without neoadjuvant CTx (total) | MSS/EBV(−) | 234 | 96 | 81.6 | 60.6 | 52.8 | 70.0 (32.7–107.3) | 1 ref. | |
| EBV(+) | 7 | 1 | 83.3 | 83.3 | 83.3 | nr | 0.26 (0.04–1.87) | 0.181 | |
| MSI‐L | 14 | 12 | 62.3 | 31.2 | 23.4 | 21.7 (1.0–42.4) | 2.21 (1.21–4.04) | 0.01 | |
| MSI‐H | 35 | 13 | 72.9 | 66.2 | 66.2 | nr | 0.81 (0.45–1.44) | 0.465 | |
| Total | 290 | 122 | 79.7 | 60.4 | 53.8 | 85.0 (52.1–117.9) | |||
| Resected tumours without neoadjuvant CTx (cT2) | MSS/EBV(−) | 107 | 30 | 91.8 | 74.7 | 70.2 | nr | 1 ref. | |
| EBV(+) | 4 | 0 | 100 | 100 | 100 | nr | 0.43† (0–3.06) | 0.495 | |
| MSI‐L | 5 | 4 | 80 | 53.3 | 26.7 | 42.2 (13.7–70.7) | 3.88† (1.24–9.51) | 0.023 | |
| MSI‐H | 12 | 3 | 72.7 | 72.7 | 72.7 | nr | 0.81† (0.22–2.20) | 0.713 | |
| Total | 128 | 37 | 89.7 | 74.5 | 69.7 | 42.2(13.7–70.7) | |||
| Resected tumours without neoadjuvant CTx (cT3/cT4) | MSS/EBV(−) | 126 | 65 | 73.4 | 48.3 | 36.7 | 29.3 (11.4–47.2) | 1 ref. | |
| EBV(+) | 3 | 1 | 66.7 | 66.7 | 66.7 | nr | 0.35 (0.05–2.56) | 0.300 | |
| MSI‐L | 9 | 8 | 55.6 | 22.2 | 22.2 | 15 (4.2–25.8) | 1.52 (0.72–3.20) | 0.272 | |
| MSI‐H | 23 | 10 | 72.9 | 62.5 | 62.5 | 85 (20.1–149.9) | 0.70 (0.36–1.36) | 0.289 | |
| Total | 161 | 84 | 72.1 | 49.2 | 40.7 | 34.3 (17.6–51) | |||
| Resected tumours after neoadjuvant CTx (total) | MSS/EBV(−) | 273 | 152 | 77.4 | 43.3 | 36 | 29.1 (24.6–33.6) | 1 ref. | |
| EBV(+) | 16 | 6 | 71.8 | 59.8 | 47.9 | 44.4 | 0.64 (0.29–1.46) | 0.290 | |
| MSI‐L | 13 | 4 | 82.5 | 70.7 | 70.7 | 62.4 | 0.64 (0.24–1.74) | 0.385 | |
| MSI‐H | 24 | 8 | 81.9 | 67.5 | 60 | nr | 0.54 (0.26–1.09) | 0.085 | |
| Total | 326 | 170 | 77.7 | 46.5 | 39 | 32.4 (23.0–41.8) | |||
| Resected tumours after neoadjuvant CTx (TRG3) | MSS/EBV(−) | 137 | 83 | 73.3 | 37.3 | 30 | 26.7 (19.2–34.2) | 1 ref. | |
| EBV(+) | 8 | 4 | 58.3 | 29.2 | 29.2 | 35.6 (0–73.6) | 0.91 (0.33–2.47) | 0.847 | |
| MSI‐L | 7 | 2 | 66.7 | 0 | 0 | nr | 0.79 (0.19–3.21) | 0.736 | |
| MSI‐H | 19 | 6 | 82.5 | 69.8 | 59.9 | nr | 0.43 (0.19–0.98) | 0.043 | |
| Total | 171 | 95 | 73.2 | 41.0 | 33.4 | 27.4 (20.8–34.0) | |||
ref., reference; nr, not reached.
*
P value of Cox's regression.
†
HRs were calculated according to Firth's correction.